CAR-T therapy for AL amyloidosis
Treatments studied
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of AL amyloidosis (a type of amyloidosis caused by abnormal plasma cells).
- The disease must be measurable through blood tests, such as high free light chains or M-protein.
- You must have received at least one prior treatment that didn't work or stopped working (relapsed/refractory disease).
- Your heart function must be good enough — no severe heart failure or very high cardiac enzyme levels.
- You cannot have had prior CAR-T cell therapy or certain other targeted immune therapies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This trial tests a new type of immunotherapy called CAR-T cells, which are engineered to attack cancer cells that have certain markers (CD19 or BCMA). It is for people with blood cancers like multiple myeloma or certain lymphomas that have not responded to multiple prior treatments. The goal is to see if this treatment can help when other options have failed.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
This trial tests a new immune cell therapy (CAR-T) that targets two markers on high-risk plasma cell cancers. It aims to see if this treatment is safe and helpful for people with aggressive or resistant forms of this disease.
This trial tests a new drug called teclistamab for people with AL amyloidosis whose disease has not responded well to previous treatments. It aims to see if the drug can help control the disease.
This study is testing a new type of cell therapy (called CAR-T) that uses your own immune cells to attack the cancer cells in plasma cell tumors. It is designed for patients with multiple myeloma, plasma cell leukemia, plasmacytoma, or amyloidosis that has returned or not responded to standard treatments.
Hear when a new Relapsed/Refractory AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.